{"nctId":"NCT00494299","briefTitle":"Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)","startDateStruct":{"date":"2006-04"},"conditions":["Carcinoma, Hepatocellular"],"count":458,"armGroups":[{"label":"Sorafenib (Nexavar, BAY43-9006)","type":"EXPERIMENTAL","interventionNames":["Drug: Sorafenib (Nexavar, BAY43-9006)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Sorafenib (Nexavar, BAY43-9006)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female\n* Aged of 18 and over\n* Advanced hepatocellular carcinoma\n\nExclusion Criteria:\n\n* History of prior systemic chemotherapy\n* Failure in vital organ","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Progression (TTP)","description":"Time to progression (TTP) was defined as the time from date of randomization to radiological progression / recurrence. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at their last date of follow-up were censored at the time of analysis.","paramType":null,"dispersionType":null,"classes":[]},{"type":"POST_HOC","title":"Number of Death Cases Due to Any Cause","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":44,"n":229},"commonTop":["HAND-FOOT SKIN REACTION","RASH/DESQUAMATION","LIPASE","METABOLIC/LAB - OTHER (SPECIFY)","DIARRHEA"]}}}